



# We are Daiichi Sankyo. *in oncology*

Every cancer journey is a unique and personal experience for patients and very complex to be fully understood. We know that every cancer patient may also be a mother or father who want to see their children smile. A partner, a friend, a daughter, a son who long to kiss and hug their loved ones. It is with this knowledge that we conduct our science and research to see another warm embrace, another smile or touch – we know how much they matter. A cancer diagnosis should not be the end of these essential moments. That is what we believe in and why we work relentlessly to answer patients' needs in the best possible way.

## Our purpose

To contribute to the enrichment of quality of life around the world.

## Our mission

To create innovative pharmaceuticals addressing diverse medical needs.

## Our vision

To become an innovative global healthcare company contributing to the sustainable development of society.

# A smile, ... a warm embrace, a kiss.

A cancer diagnosis should not mean the end of the essential moments in life. That is what we at Daiichi Sankyo believe in and why we work relentlessly to answer patients' needs in the best possible way.

- **High unmet medical need**

We focus our work on areas where new treatments are needed. We know that addressing these areas requires passion and a never-ending relentlessness.

- **No two cancers are alike**

We believe in a holistic approach to cancer that looks at the entire human being and not just the disease. Each patient is unique and so is each patient's situation.

- **Importance of early detection**

Spotting cancer early increases the chances of survival. We raise awareness for the signs and symptoms of cancer and encourage improved access to screenings to help early detection.



## OUR AMBITION IS TO CREATE THE



Breast cancer

531,000\*



Gastric cancer

136,000\*



Lung cancer

477,534\*

## TREATMENTS OF TOMORROW



Colorectal cancer



Haematological cancer



Other solid tumours

\*Estimated new cases diagnosed in Europe  
 Source: <https://www.uicc.org/news/globocan-2020-new-global-cancer-data>

## Changing how cancer is treated today with **PASSION FOR INNOVATION**

### ADC Experts\*

With our Antibody-Drug Conjugates we have developed a new platform technology across tumour-types.

### 7 Improvements

We have addressed 7 critical limitations of ADCs and improved them.

### Linker Technology


Our technology is the backbone of our innovative oncology portfolio.

### • Own R&D labs

Our innovations derive from our own research, conducted in our own labs.

### • Other Molecules

We go beyond ADCs and have other first-in-class innovations in our pipeline.




## We make therapies accessible as quickly as possible. **INVESTMENTS**

• **> €11 billion**  
R&D investment  
(2021 – 2026)<sup>7</sup>

• **> 24%**  
R&D expenses of yearly revenue  
(€1.95 billion)<sup>8</sup>

## EU APPROVALS



<sup>1</sup> Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. SmPC at [www.ema.europa.eu](http://www.ema.europa.eu).

<sup>2</sup> Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. SmPC at [www.ema.europa.eu](http://www.ema.europa.eu).

<sup>3</sup> Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. SmPC at [www.ema.europa.eu](http://www.ema.europa.eu).

<sup>4</sup> Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. SmPC at [www.ema.europa.eu](http://www.ema.europa.eu).

<sup>5</sup> Trastuzumab deruxtecan as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. SmPC at [www.ema.europa.eu](http://www.ema.europa.eu).

<sup>6</sup> Quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive. SmPC at [www.ema.europa.eu](http://www.ema.europa.eu).

<sup>7</sup> [https://www.daiichisankyo.com/files/investors/library/materials/2021/20210405\\_5th\\_MTP\\_E.pdf](https://www.daiichisankyo.com/files/investors/library/materials/2021/20210405_5th_MTP_E.pdf)

<sup>8</sup> [https://www.daiichisankyo.com/files/investors/library/quarterly\\_result/2022/FY2022\\_Q4\\_Financial\\_Results\\_Presentation\\_E\\_2.pdf](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2022/FY2022_Q4_Financial_Results_Presentation_E_2.pdf)

\*Antibody-Drug Conjugates (ADCs) are a class of cancer therapies that combine antigen specificity and potent cytotoxicity in a single molecule.<sup>1,2</sup>

We want to go beyond making incremental differences.

● **13 European affiliates + Canada**

> 2,500 European employees

● **> 17,000**

employees worldwide

● **20**

countries ground presence

● **18**

R&D locations in 10 countries

● **13**

manufacturing locations in 6 countries



**Pfaffenhofen**  
European  
manufacturing site



**Munich**  
European headquarter

For over 120 years we have pioneered cutting-edge science, starting from the discovery of vitamin B<sub>1</sub> by one of our scientists, and launching the first adrenaline agent in the early 1900s, to the launches of new oncology therapies in the 21st century. Our heritage inspires us to rise to new challenges with continuous innovation.

Success relies on cooperation - researchers, clinicians, nurses, advocates, and more - everyone plays a part. Only by working together, and applying our individual expertise with compassion, we may craft better outcomes for the patients of today and tomorrow...

*Happy to connect*